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Abstract
Objective. To describe the long-term outcomes of patients with Takayasu arteritis (TAK) and renal ar-
tery involvement (RAI).
Methods. A retrospective review of 122 patients with TAK at three tertiary centres in Canada,
Sweden and the UK. Data on demographics, laboratory and clinical parameters, medications and angi-
ography findings were collected. Non-renal and renal parameters were compared at baseline and fol-
low-up.
Results. A total of 37 patients (30%) with RAI were identified: 18 (49%) with unilateral and 19 (51%)
with bilateral RAI. Patients were predominantly female (89%). The median age at diagnosis was
27 years [interquartile range (IQR) 16–38]. The median follow-up time was 7 years (IQR 2–12).
Hypertension was seen in 27 patients (73%) at presentation and 25 (68%) at follow-up. The median
estimated glomerular filtration (eGFR) at presentation was 94 and 98 ml/min/1.73 m2 in those with uni-
lateral and bilateral RAI, respectively. The corresponding median eGFR at follow-up was 101.5 and
104 ml/min/1.73 m2, respectively. Three patients at presentation and two at follow-up had an eGFR of
<60 ml/min/1.73 m2. Five underwent endovascular intervention and three required surgical interven-
tions. Among the 33 patients with radiologic follow-up, 23 (69%) had persistent RAI and 10 (30%) had
resolution of RAI. One (6%) patient with unilateral RAI developed bilateral RAI and three (19%) with bi-
lateral RAI regressed to unilateral RAI. Over time, 23 (62%) patients had stable renal function, 7 (19%)
had improvement and 4 had a decline in renal function; no patient developed end-stage renal disease
(ESRD).
Conclusion. In this series of TAK patients with RAI, long-term non-renal and renal outcomes were
favourable. No patient experienced ESRD or died.
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Introduction
Takayasu arteritis (TAK) is a chronic inflammatory large
vessel vasculitis of unknown aetiology characterized by
granulomatous inflammation of the aorta and its
branches [1]. It predominantly affects women <40 years
of age. It has an incidence of 0.3–2.6 cases per million
in Europe and North America; the incidence is higher in
Asian and Indian populations [2–4].
TAK is characterized by an early inflammatory phase
manifested as non-specific systemic symptoms that of-
ten lead to a delay in diagnosis. The chronic inflamma-
tory process leads to vascular stenosis over a period of
months (aneurysms can also occur), resulting in end-
organ damage and symptoms of ischaemia character-
ized by limb claudication, abdominal or chest pain,
stroke and/or presyncope [4]. During this later phase,
patients are often found to have reduced or absent arte-
rial pulses, asymmetric blood pressures or aortic mur-
murs secondary to aortic root involvement. Long-term
morbidity results from systemic and pulmonary
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hypertension, angina, aortic insufficiency, stroke and re-
duced quality of life [4, 5].
The reported incidence of renal artery involvement
(RAI) in TAK is 8–38% [3, 4, 6–11]. RAI is described as a
poor prognostic factor that leads to renal artery steno-
sis, renovascular hypertension often refractory to antihy-
pertensive therapy [4, 6, 7, 12] and renal insufficiency
[11]. There are correlations between renovascular hyper-
tension and cardiovascular morbidity and mortality;
pregnancy is often discouraged due to feared complica-
tions such as pre-eclampsia [13]. However, there are
limited data on the long-term outcomes of patients with
TAK and RAI [11]. Here we report the long-term out-
comes of 37 patients with TAK and RAI from three
centres in Canada, Sweden and the UK.
Methods
A retrospective review of all patients with TAK was per-
formed at the Vasculitis Clinic, Addenbrooke’s Hospital,
Cambridge, UK; the Department of Rheumatology, Lund
University Hospital, Lund, Sweden and the Vasculitis
Clinic, Mount Sinai Hospital, Toronto, Ontario, Canada.
The diagnosis of TAK was based on constitutional symp-
toms, elevated inflammatory markers and positive angiog-
raphy showing arterial wall thickening and stenosis, with/
without aneurysm. A diagnosis of RAI required positive
angiography—either conventional catheter angiography,
CT angiography or magnetic resonance angiography. All
imaging was systematically evaluated for RAI.
Data collection
Medical records were reviewed at baseline and follow-up.
The baseline was defined as the time of diagnosis of RAI.
Follow-up was defined as the last patient visit. Data were
collected on demographics, comorbidities, presenting
symptoms and signs, presence of hypertension and prior
and current medications. Laboratory values including creati-
nine, ESR, and CRP were reviewed. Data on vessel wall in-
volvement and severity were obtained from imaging
reports. Data were used to determine whether the ACR
classification criteria for TAK were met [14]. When available,
results from histology, technetium-99m (Tc99m) mercaptoa-
cetyltriglycine scans and endovascular interventions were
reviewed. Estimated glomerular filtration (eGFR) was calcu-
lated based on the Chronic Kidney Disease Epidemiology
Collaboration equation [15]. Disease activity was scored at
baseline (presentation with RAI) and follow-up using the
Indian Takayasu Activity Index 2010 (ITAS2010) on a scale
of 0–51 [16]. Organ damage was assessed at the last
follow-up on a scale of 0–8 using the Vasculitis Damage
Index [17].
Hypertension was defined as a systolic blood pressure
>140mmHg or a diastolic blood pressure >90mmHg or
a normal blood pressure on antihypertensive medications.
Worsening renal function was defined as a decrease in
the eGFR >20% over the follow-up period and improve-
ment in renal function was defined as an increase in
eGFR >20%. Stable renal function was defined as a
change in the eGFR of <20%. Renal size asymmetry was
determined subjectively as reported by the reading radiol-
ogist on ultrasound, Tc99m mercaptoacetyltriglycine scan
or angiography. Resolution of size asymmetry required
the renal size to be normal bilaterally. Angiography was
classified as stable if reported by the radiologist on fol-
low-up imaging.
Statistical analyses
Data from all three sites were pooled. Descriptive analy-
ses were used to describe the cohort. Data are pre-
sented as median and interquartile (IQR) range, mean
and range or number and percentage unless stated
otherwise.
Ethics
In accordance with UK National Health Service
Research Ethics Committee guidelines, ethical approval
was not required for this work because it comprises ret-
rospective data and all treatment decisions were made
prior to our evaluation. Patients seen in Canada pro-
vided informed and written consent to participate in the
clinic database for the purpose of data collection. Study
approval was obtained through the Mount Sinai Hospital
Research Ethics Board (Research Ethics Application
14-0052-D Vasculitis Database). The study was also ap-




A total of 122 cases with TAK were reviewed for RAI.
Ten of 37 (27%) had RAI in the UK cohort, 6/13 (46%) in
the Swedish cohort and 21/72 (29%) in the Canadian
cohort. Overall, there were 37/122 TAK patients with RAI
Key messages
. The prevalence of renal artery involvement in this Takayasu arteritis cohort is comparable to that of published
cohorts.
. Long-term outcomes of renal artery involvement in this Takayasu arteritis cohort were relatively good.
. No patient developed end-stage renal disease during the study period.
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(30%). Among these 37 patients, 18 patients (49%) had
unilateral and 19 (51%) had bilateral involvement
(Table 1). The severity of RAI was variable, ranging from
mild/thickening/ectasia to severe/tight/high grade.
Baseline patient demographics are summarized in
Table 2. Thirty-three patients (89%) were female. The
median age at diagnosis was 27 years (IQR 16–38).
Seven were >40 years of age, including four >60 years
of age; these patients did not have symptoms
suggestive of nor did they meet ACR classification
criteria for GCA [18]. Among the UK and Canadian
cohorts, the median disease duration at first radiologic
assessment was 0.5 years (IQR 0.2–2) but ranged from
0 to 26 years.
Twenty-nine patients (78%) met the ACR classification
criteria for TAK. Six of eight patients that did not meet
the criteria were young (between 9 and 18 years), one
was 33 years and another was 64 years. All were diag-
nosed on the basis of positive angiography and elevated
inflammatory markers, the latter not being an ACR crite-
rion. At baseline, 22 patients (59%) had asymmetric
blood pressures between arms, 19 (51%) had reduced
brachial pulses, 16 (43%) reported symptoms of limb
claudication and 13 (35%) had audible subclavian or ab-
dominal bruits.
At diagnosis of RAI, 34 patients (91%) had elevated
inflammatory markers. The median baseline CRP was
29mg/l (IQR 9–57) and the median ESR was 44mm/h
(IQR 34–84). ITAS2010 scores were available at presen-
tation in 35/37 patients; the median ITAS2010 was
13 (IQR 9–15).
Twenty-nine of 37 patients (78%) had comorbidities at
diagnosis of RAI, which are summarized in Table 2. Pre-
existing hypertension was present in 19 patients (51%).
Two (5%) had pre-existing structural renal disease, includ-
ing pelvi-ureteric junction obstruction with hydronephrosis
and undefined renal surgery with hydronephrosis. SpA
was present in six patients (16%), IBD in 3 (8%), psoriasis
in 2 (5%) and seronegative arthropathy in 1 (3%). Three
patients (8%) had previously been treated for
tuberculosis.
Fourteen patients (38%) were treatment naı¨ve at the
diagnosis of RAI. Twenty-one patients (57%) had
received prior systemic treatments (Table 2), including glu-
cocorticoids (GCs) and immunosuppressive drugs (ISDs).
Eight (22%) received GCs alone, 10 (27%) received GCs
and one or more ISD and 3 (8%) received infliximab with
or without GC/ISD. The most common ISDs were AZA (six
patients), CYC (two patients) and MTX (two patients).
MMF and ciclosporin were used in one patient each.
Follow-up
The median follow-up was 7 years (IQR 2–12) but ranged
from 0 to 30 years. During that period of time, patients
received both systemic and vascular treatments specific
to RAI (Table 3).
In terms of systemic treatments, GCs alone were
used in 4 patients (11%) and GCs in combination with
an ISD in 29 (78%); 4 patients (11%) did not receive
systemic therapy.
Conventional ISDs alone were used in 19 (51%)
patients, most commonly AZA and MTX. Biologics were
used in 10 (27%) patients: infliximab in 7 (19%), adali-
mumab in 2 (5%), and rituximab in 2 (5%). Abatacept
was used in two patients (5%). Some patients received
more than one biologic drug during the follow-up period,
but not concurrently. At the last follow-up, 22 patients
(59%) remained on GCs, among which at least 12 (32%)
were on >5mg/day of prednisone equivalent. Eight
patients (21%) were on GCs alone. Twenty patients
(54%) were on an ISD, most commonly AZA or MTX,
TABLE 1 Renal and non-renal parameters according to baseline RAI
Unilateral RAI (n5 18) Bilateral RAI (n5 19)
Baseline Follow-up Baseline Follow-up
RAI, n (%)
Unilateral 18 (100) 9 (50) 0 (0) 3 (16)
Bilateral 0 (0) 1 (6) 19 (100) 10 (53)
Normal N/A 7 (39) N/A 3 (16)
No data N/A 1 (6) N/A 3 (16)
Renal parameters, n (%)
HT 11 (61) 10 (56) 16 (84) 15 (79)
eGFR, median (IQR) 94 (86–107) 101.5 (85–107) 98 (73–135) 104 (89–124)
GFR <60 ml/min/1.73 m2, n (%) 1 (6) 1 (6) 2 (11) 2 (11)
Renal asymmetry, n (%) 5 (28) 5 (28) 5 (26) 5 (26)
Non-renal parameters, median (IQR)
ITAS2010 13 (9–15) 3 (0–6) 12 (9–14) 1 (0.5–5.5)
ESR 43 (32–55) 16 (10–24) 59 (36–101) 13 (8–27)
CRP 29 (9–45) 4.5 (2–20) 28 (13–65) 3.2 (1–6)
VDI N/A 4.5 (3–5) N/A 4 (3–7)
HT: hypertension; VDI: Vasculitis Damage Index.
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including two who were receiving rituximab and two
who were receiving infliximab in addition to a conven-
tional ISD. Nine were not receiving systemic therapy.
The median number of antihypertensive agents was 1
(IQR 0–2, range 0–6).
For vascular treatments, seven patients underwent
eight vascular and/or surgical interventions for RAI, in-
cluding five patients (14%) who had endovascular inter-
vention (renal angioplasty and/or stent placement) and
three patients (8%) who had surgical intervention.
Among the five former patients, two had angioplasty
alone (successful in one) and three had angioplasty
with endovascular stent placement, including one who
required successful rescue angioplasty after endovascu-
lar stent collapse. Among the three who underwent sur-
gical intervention, one who had no systemic therapy
underwent successful bilateral renal artery bypass, one
underwent unilateral renal artery bypass (failed) with
subsequent nephrectomy and one underwent splenore-
nal shunt (failed) subsequent to bilateral renal artery
endovascular stent placement complicated by endovas-
cular thrombosis, ultimately resulting in nephrectomy.
Outcomes
Table 1 summarizes renal and non-renal parameters at
baseline (diagnosis of RAI) and follow-up stratified
according to baseline RAI (unilateral vs bilateral). Follow-
up angiography was available for 33 patients (89%). Ten
patients (27%) had resolution of RAI.
Among the 18 patients (49%) with unilateral involve-
ment at baseline, 9 (50%) had persistent unilateral RAI,
1 (6%) had progressed to develop bilateral RAI, 7 (39%)
had resolution of RAI at follow-up and 1 (6%) had no
follow-up angiography. Two patients with persistent uni-
lateral RAI had reduced radiographic severity. Of those
with resolution of RAI, one had a ‘high-grade’ stenosis
and received systemic therapy and angioplasty, five re-
ceived systemic therapy alone and one received no
treatment.
Among the 19 patients (51%) with bilateral disease at
baseline, 10 (53%) had persistent bilateral RAI at follow-
up, 3 (16%) had improvement with unilateral RAI and
3 (16%) had complete resolution; follow-up data were
not available for 3 (16%) patients. Two patients with per-
sistent bilateral RAI had improvement in the severity of
RAI and in six patients the severity remained the same;
there were inadequate baseline data to comment on the
change in severity for two patients. There was no
follow-up angiography for three patients. All three
patients with unilateral RAI at follow-up received sys-
temic therapy, including an aforementioned patient who
underwent splenorenal shunt complicated by nephrec-
tomy. All three patients with complete resolution of RAI
at follow-up received systemic therapy and one under-
went angioplasty.
Twenty-seven patients (73%) were hypertensive or
on antihypertensive therapies at the diagnosis of RAI,
including 11 (61%) with unilateral and 16 (84%) with
bilateral RAI (Table 1). In 10 patients, hypertension








Unilateral RAI, n (%) 18 (49)
Bilateral RAI, n (%) 19 (51)
Female, n (%) 33 (89)






Disease duration, median (IQR), years 0.5 (0.2–2)
ACR classification met, n (%) 29 (78)
Disease features, n (%)
Asymmetrical blood pressure 22 (59)
Reduced brachial pulse 19 (51)
Limb claudication 16 (43)
Bruit 13 (35)




Treated tuberculosis 3 (8)
Structural renal disease 2 (5)
Prior treatments, n (%)
None 14 (38)
Systemic treatments 21 (57)
GC only 8 (22)
GC þmore than one ISD 10 (27)
IFX6 GC þ ISD 3 (8)
Endovascular intervention 2 (5)
CABG 1 (3)
aOther: Arabic (2), Hispanic (2), South Asian (2), undefined
(1).
bSpA: IBD, psoriasis, seronegative inflammatory arthritis.
CABG: coronary artery bypass graft; IFX: infliximab.
TABLE 3 Pharmacologic and vascular treatments adminis-





Systemic treatments, n (%)
GC alone 0 (0) 4 (21)
ISD6 GC 15 (83) 14 (73)
None 3 (16) 1 (5)
Number of antihypertensives,
median (IQR)
1 (0–1.75) 1 (0.5–3)
Vascular treatments, n (%)
Endovascular 2 (11) 3 (16)
Surgical 1 (6) 2 (11)
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predated the diagnosis of TAK, including one with pre-
existing gestational hypertension. At follow-up, 25 (68%)
patients had hypertension, including 10 (56%) with uni-
lateral and 15 (79%) with bilateral RAI; 24/25 (96%)
were on antihypertensive agents. Of these, 23 (92%)
had hypertension at baseline. Four of 27 patients (15%)
with hypertension at baseline were no longer hyperten-
sive or on antihypertensive therapy at follow-up (2 with
bilateral RAI at baseline). Among those with hyperten-
sion at follow-up, the median number of antihyperten-
sive agents was 1 (IQR 1–3, range 0–6).
The median eGFR at diagnosis with RAI was 94 ml/
min/1.73 m2 (IQR 86–107) and 98 (73–135) for patients
with unilateral and bilateral RAI, respectively. At follow-
up this was largely unchanged (Table 1). Over the
follow-up period, 7 showed an improvement in eGFR,
4 showed a decline and 21 had no change; follow-up
eGFR was not available for 5 patients. At presentation
with RAI, three patients (8%) were noted to have an
eGFR <60 ml/min/1.73 m2 but >45. One had severe
unilateral disease and two had bilateral disease. All three
patients had renal asymmetry. Among the three present-
ing with eGFR <60 ml/min/1.73 m2, one patient showed
an improvement in eGFR, one maintained eGFR and
one had a worsening of eGFR in the context of known
pre-existing pelvi-ureteric junction obstruction. At follow-
up, two had an eGFR <60 ml/min/1.73 m2, including
one patient who previously had a normal eGFR.
Renal size asymmetry was present in 10 patients
(27%) at diagnosis of RAI, including 5 (28%) with unilat-
eral and 5 (26%) with bilateral disease, and was absent
in 21 patients (57%). Data on renal asymmetry at the di-
agnosis of RAI were not available for six patients (16%);
however, two of these patients had no asymmetry on
angiography on the next available imaging. Two patients
with renal asymmetry at the diagnosis of RAI had pre-
existing structural defects, including pelvi-ureteric junc-
tion obstruction and hydronephrosis and undefined prior
renal surgery. One patient was referred after failed stent
placement. At follow-up, 10 patients (27%) had renal
asymmetry, including 3 who developed new renal
asymmetry, 2 of whom underwent nephrectomy. The
remaining seven patients had pre-existing renal asym-
metry. Three with renal size asymmetry at baseline had
normalization of renal symmetry at follow-up. Renal
symmetry data at follow-up were unavailable for two
patients. Two other patients had no follow-up data
available, but an angiogram done earlier showed no
renal asymmetry.
Disease activity and organ damage
Follow-up ITAS2010 scores were available in 31/37
patients and the median was 2 (IQR 0–6). Overall, 28
patients experienced a reduction in the ITAS2010 score,
indicating a reduction in disease activity. Two patients
had stable ITAS2010 scores. In six, follow-up ITAS2010
scores were not available and in one a baseline
ITAS2010 score was not available, making comparison
impossible. The median Vasculitis Damage Index score
at follow-up was 4 (IQR 3–5). The most common dam-
age items recorded were major vessel stenosis (n¼34),
diastolic hypertension (n¼22), claudication >3months
(n¼16), absent pulse (n¼ 12) and valvular heart disease
(n¼11).
Pregnancies
Eight patients in the Canadian and Swedish cohorts had
12 pregnancies resulting in 8 healthy infants during the
follow-up period. There were three therapeutic abor-
tions. There were no maternal or foetal deaths.
Four patients with unilateral disease, including three
with severe RAI, had six pregnancies resulting in four
live healthy infants. Among the three with severe unilat-
eral RAI, one was delivered by caesarean section at
36weeks due to hypertension and severe oligohydram-
nios, one was delivered at term and one was therapeuti-
cally aborted at 9weeks. One patient with unilateral RAI
(undefined severity) had two healthy pregnancies and
one therapeutic abortion.
Four patients with bilateral disease, including one with
severe bilateral RAI, had six pregnancies resulting in
four healthy infants. The patient with severe bilateral RAI
delivered at 36weeks gestation by caesarean section
for severe gestational hypertension, one patient with
mild bilateral RAI had two healthy pregnancies, one by
normal vaginal delivery and one by caesarean section,
and there was one therapeutic abortion. One patient
with bilateral undefined RAI delivered at term by caesar-
ean section. One patient with mild bilateral RAI was still
pregnant during the study period.
Discussion
To our knowledge, this is the first publication describing
the long-term outcomes of TAK with RAI in an ethnically
diverse western cohort. The 30% prevalence of RAI in-
volvement in the three cohorts studied here is compara-
ble to that previously reported (8–46%) [3, 4, 6–8, 11,
19, 20], although it is higher than in Japanese cohorts
[9, 10].
Hong et al. [11] recently described long-term out-
comes of RAI in a Korean cohort of TAK patients.
However, there are important differences in the study
population and design as compared with our study. Our
cohort is younger, more Caucasian and more ethnically
diverse. Our cohort had similar rates of RAI and baseline
and follow-up eGFRs, however, hypertension, refractory
hypertension and death were less frequent. This may be
attributed to milder disease, although it is difficult to
compare. Hong et al. [11] did not include disease activ-
ity scores. Finally, while our study is a basic descriptive
analysis, the Hong et al. study compares outcomes by
vascular interventions.
ACR classification criteria were met in 78% of our
patients. These criteria have limited utility in clinical
practice, as four of the six criteria present late-disease
findings rather than systemic signs, which present earlier
Longterm outcomes of Takayasu Arteritis
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in the disease course. All our patients had abnormal
angiograms suggestive of TAK, the majority had ele-
vated inflammatory markers and all presented with
systemic and vascular symptoms and signs highly sug-
gestive for TAK. None presented with features of or met
the criteria for GCA; these patients presumably had
undiagnosed arterial lesions years before clinical diagno-
sis. The predominance of females and the mean age of
our cohort are comparable to previous reports [3, 4, 6,
8, 10, 19, 20].
Hypertension was the most commonly reported pre-
existing comorbidity in our study, occurring in 51% of
patients, which is significantly more frequent than many
published cohorts but similar to the previously published
cohort of patients with TAK and RAI [11]. This may be
due to underlying RAI; a study comparing TAK patients
with and without RAI would elucidate this. The majority
of patients were on antihypertensive agents at follow-
up. Interestingly, we noticed an increased association of
SpA features, including IBD, which has been previously
described [21, 22], as well as seronegative inflammatory
arthritis and psoriasis. The incidence of previously
treated tuberculosis was elevated and has been previ-
ously linked to TAK [23].
The median follow-up period of patients was 7 years.
The four with a decline in renal function had a longer
follow-up period (range 7–24 years), which may account
for this decline. During the follow-up period the majority
of patients were on systemic therapies. A minority
underwent vascular interventions for severe RAI, includ-
ing both endovascular and surgical repair, and half of
these were complicated. Despite poor angiographic out-
comes, these patients did not experience end-stage
renal disease (ESRD).
RAI in TAK is commonly described as a poor prog-
nostic marker due to its association with renovascular
hypertension and subsequent complications, but there
are few data to support this [4, 6, 7, 12]. The results of
this study are reassuring, as in the majority of patients,
angiography results improved over time. Renal asymme-
try was uncommon at baseline and, when present, was
associated with structural renal disease; patients did not
develop renal asymmetry over time. Hypertension was
common at baseline and follow-up; however, the major-
ity of patients were not on more than three antihyperten-
sive agents. The majority of patients had normal eGFRs
at baseline and follow-up. In general, eGFRs were stable
over time, with eGFRs declining in only four patients.
The lowest eGFR was still >40 ml/min/1.73 m2, repre-
senting stage 3B chronic kidney disease; none of our
patients experienced ESRD and there were no deaths.
Overall, the study demonstrates that the long-term renal
and survival outcomes of TAK patients with RAI are
more favourable than previously thought in an ethnically
diverse western cohort.
Pregnancy outcomes in this TAK cohort were favour-
able and comparable to other published cohorts
[24–26]. While gestational hypertension resulted in pre-
term caesarean section, there were no reports of pre-
eclampsia and no maternal or foetal deaths. Data on
miscarriages were not recorded.
The strengths of this study include the relatively large
size of the cohort of ethnically diverse patients with a
rare disease from multiple sites and the length of follow-
up and retention over time. However, the study is limited
by the nature of its design as a retrospective chart re-
view, leading to some missing data and potential inac-
curacies in activity and damage assessment. It is also
not possible to assess the contribution of expert multi-
disciplinary management in disease outcomes.
In conclusion, our study demonstrated a favourable
long-term outcome of RAI in a large, multicentre, ethni-
cally diverse cohort of patients with TAK. Renal outcomes
were favourable regardless of unilateral or bilateral dis-
ease and disease severity. However, the impact of the
clinical care of these patients at expert vasculitis centres,
with long-term systemic and antihypertensive therapy,
may have impacted the outcomes.
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